Role of CD8(+) T Cells in Protection Against Leishmania Donovani Infection in Healed Visceral Leishmaniasis Individuals

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2014 Dec 5

PMID 25471494

Citations 27

Authors

Himanshu Kaushal

Rachel Bras-Goncalves

Narender Singh Negi

Jean-Loup Lemesre

Gerard Papierok

Poonam Salotra

Affiliations

Soon will be listed here.

Abstract

Background: Majority of individuals with history of visceral leishmaniasis (VL) exhibit strong immunity to re-infection, however, the mechanism of resistance is poorly understood. It is unclear whether CD8(+) T cells contribute to protection against Leishmania donovani infection through cytotoxic activity. The present study aims to evaluate immunological mechanism associated with resistance to the disease in healed VL (HVL) individuals and further, the contribution of CD8(+) T cells in the protective immunity.

Methods: Peripheral blood mononuclear cells (PBMCs) from VL, HVL and naive groups were exposed in vitro to total soluble Leishmania antigen (TSLA) from L. donovani. The proliferation index was determined by ELISA based lymphoproliferative assay. Cytokines and granzyme B levels were measured by CBA. Activated T-cell populations were estimated using flow cytometry.

Results: We observed significantly higher lymphoproliferation, cytokines and granzyme B levels in HVL group compared to naive or VL group. More strikingly, we found a strong association (rs = 0.895, P < 0.0001) between proliferation index (PI) and granzyme B level, with a significant proportion of activated CD8(+) T cells in HVL group.

Conclusions: Leishmania immune group (HVL) exhibited durable and strong cellular immune response to TSLA in terms of lymphoproliferation as well as production of Th1 cytokines and granzyme B. Additionally, the elevated level of activated CD8(+) T cells and stimulation of cytotoxic activity through granzyme B production, indicated a possible role of CD8(+) T cells in resistance to L. donovani infection in the HVL group.

Citing Articles

Molecular Insights into Cell-Mediated Immunity in Atypical Non-Ulcerated Cutaneous Leishmaniasis.

Batista L, Sandoval Pacheco C, Flores G, Ferreira F, Goncalves A, Sosa-Ochoa W Microorganisms. 2025; 13(2).

PMID: 40005779 PMC: 11858551. DOI: 10.3390/microorganisms13020413.

The development and maintenance of immunity against visceral leishmaniasis.

Tiwari R, Kumar A, Singh V, Rajneesh , Bhushan Chauhan S, Sundar S Front Immunol. 2025; 15:1486407.

PMID: 39781380 PMC: 11707418. DOI: 10.3389/fimmu.2024.1486407.

Chemokines Signature and T Cell Dynamics in Leishmaniasis: Molecular insight and therapeutic application.

Upadhyay S, Kumar S, Singh V, Tiwari R, Kumar A, Sundar S Expert Rev Mol Med. 2024; 1-55.

PMID: 39587036 PMC: 11707835. DOI: 10.1017/erm.2024.36.

Advances in Vaccines: Current Development and Future Prospects.

Ayala A, Llanes A, Lleonart R, Restrepo C Pathogens. 2024; 13(9).

PMID: 39339003 PMC: 11435054. DOI: 10.3390/pathogens13090812.

A Prospective cohort study of zoonotic cutaneous leishmaniasis in tunisia: Clinical and Immunological features and immune correlates of protection.

Naouar I, Kammoun Rebai W, Salah A, Bouguerra H, Toumi A, Hamida N PLoS Negl Trop Dis. 2023; 17(12):e0011784.

PMID: 38064516 PMC: 10732404. DOI: 10.1371/journal.pntd.0011784.

References

Ghalib H, Whittle J, Kubin M, Hashim F, El-Hassan A, Grabstein K . IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol. 1995; 154(9):4623-9. View

Hailu A, Menon J, Berhe N, Gedamu L, Hassard T, Kager P . Distinct immunity in patients with visceral leishmaniasis from that in subclinically infected and drug-cured people: implications for the mechanism underlying drug cure. J Infect Dis. 2001; 184(1):112-5. DOI: 10.1086/320994. View

Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S . IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol. 2007; 179(8):5592-603. DOI: 10.4049/jimmunol.179.8.5592. View

McElhaney J, Pinkoski M, Upshaw C, Bleackley R . The cell-mediated cytotoxic response to influenza vaccination using an assay for granzyme B activity. J Immunol Methods. 1996; 190(1):11-20. DOI: 10.1016/0022-1759(95)00235-9. View

Ramesh V, Singh R, Salotra P . Short communication: post-kala-azar dermal leishmaniasis--an appraisal. Trop Med Int Health. 2007; 12(7):848-51. DOI: 10.1111/j.1365-3156.2007.01854.x. View

Haldar J, Ghose S, Saha K, Ghose A . Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun. 1983; 42(2):702-7. PMC: 264486. DOI: 10.1128/iai.42.2.702-707.1983. View

Barral-Netto M, Barral A, Brodskyn C, Carvalho E, Reed S . Cytotoxicity in human mucosal and cutaneous leishmaniasis. Parasite Immunol. 1995; 17(1):21-8. DOI: 10.1111/j.1365-3024.1995.tb00962.x. View

Arva E, Andersson B . Kinetics of cytokine release and expression of lymphocyte cell-surface activation markers after in vitro stimulation of human peripheral blood mononuclear cells with Streptococcus pneumoniae. Scand J Immunol. 1999; 49(3):237-43. DOI: 10.1046/j.1365-3083.1999.00470.x. View

Wizel B, Palmieri M, Mendoza C, Arana B, Sidney J, Sette A . Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. J Clin Invest. 1998; 102(5):1062-71. PMC: 508973. DOI: 10.1172/JCI3835. View

10.

Gough D, Levy D, Johnstone R, Clarke C . IFNgamma signaling-does it mean JAK-STAT?. Cytokine Growth Factor Rev. 2008; 19(5-6):383-94. DOI: 10.1016/j.cytogfr.2008.08.004. View

11.

Peruhype-Magalhaes V, Martins-Filho O, Prata A, Silva L, Rabello A, Teixeira-Carvalho A . Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania.... Clin Exp Immunol. 2006; 146(1):124-32. PMC: 1809731. DOI: 10.1111/j.1365-2249.2006.03171.x. View

12.

Lowin B, Hahne M, Mattmann C, Tschopp J . Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature. 1994; 370(6491):650-2. DOI: 10.1038/370650a0. View

13.

Bousoffara T, Louzir H, Salah A, Dellagi K . Analysis of granzyme B activity as a surrogate marker of Leishmania-specific cell-mediated cytotoxicity in zoonotic cutaneous leishmaniasis. J Infect Dis. 2004; 189(7):1265-73. DOI: 10.1086/382031. View

14.

Sharp M, Terada K, Wilson A, Nader S, Kinchington P, Ruyechan W . Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis. 1992; 165(5):852-8. DOI: 10.1093/infdis/165.5.852. View

15.

MANSON-BAHR P . Immunity in kala-azar. Trans R Soc Trop Med Hyg. 1961; 55:550-5. DOI: 10.1016/0035-9203(61)90078-5. View

16.

Griffiths G, Mueller C . Expression of perforin and granzymes in vivo: potential diagnostic markers for activated cytotoxic cells. Immunol Today. 1991; 12(11):415-9. DOI: 10.1016/0167-5699(91)90145-J. View

17.

Sacks D, Noben-Trauth N . The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002; 2(11):845-58. DOI: 10.1038/nri933. View

18.

Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S . Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994; 265(5171):528-30. DOI: 10.1126/science.7518614. View

19.

Kubar J, Fragaki K . Recombinant DNA-derived leishmania proteins: from the laboratory to the field. Lancet Infect Dis. 2005; 5(2):107-14. DOI: 10.1016/S1473-3099(05)01282-X. View

20.

. Control of the leishmaniases. World Health Organ Tech Rep Ser. 2011; (949):xii-xiii, 1-186, back cover. View